Flavonolignans reduce platelet activityFlavonolignans inhibit the arachidonic acid pathway in blood platelets.
We aimed to explore how flavonolignans from silybum marianum, specifically silybin, silychristin, and silydianin, affect blood clotting through the COX pathway in platelets. Our methods involved analyzing platelet aggregation and the formation of COX pathway metabolites.
The findings were promising; these compounds showed a reduction in platelet aggregation and COX activity. Silychristin and silybin emerged as the most effective inhibitors, potentially acting as competitive blockers at the active COX site. This suggests that flavonolignans might offer new avenues for antiplatelet and anti-inflammatory therapies.
Read More
Silibinin shows promise for COVID-19Silibinin as potential tool against SARS-Cov-2: In silico spike receptor-binding domain and main protease molecular docking analysis, and in vitro endothelial protective effects.
We explored silibinin from Silybum marianum as a potential treatment against SARS-CoV-2, focusing on its anti-inflammatory and anticoagulant effects. Through in silico analysis, we found that silibinin effectively binds to key viral proteins, suggesting it could inhibit the virus's entry and replication.
Our in vitro studies showed that silibinin also reduces expressions of proinflammatory genes linked to blood clotting. Overall, while silibinin shows promise, the need for more comprehensive clinical trials is crucial to fully understand its therapeutic potential against COVID-19.
Read More